NCT07484022 2026-03-19
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Generate Biomedicines
Phase 1 Not yet recruiting
Generate Biomedicines
University Health Network, Toronto
University Health Network, Toronto
University of Alberta
M.D. Anderson Cancer Center
NYU Langone Health
Montefiore Medical Center
Comprehensive Cancer Center Munich (CCCM)